Pharmacological insights into autophagy modulation in autoimmune diseases.
10.1016/j.apsb.2021.03.026
- Author:
Ming-Yue WU
1
;
Er-Jin WANG
1
;
Du FENG
2
;
Min LI
3
;
Richard D YE
4
;
Jia-Hong LU
1
Author Information
1. State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau 9999078, China.
2. Key Laboratory of Protein Modification and Degradation, State Key Laboratory of Respiratory Disease, College of Basic Medical Science, Guangzhou Medical University, Guangzhou 510000, China.
3. School of Pharmaceutical Sciences, National and Local United Engineering Lab of Druggability and New Drugs Evaluation, Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, Sun Yat-sen University, Guangzhou 510000, China.
4. Kobilka Institute of Innovative Drug Discovery, School of Life and Health Sciences, the Chinese University of Hong Kong, Shenzhen 518000, China.
- Publication Type:Review
- Keywords:
Autoimmune disease;
Autophagy;
Autophagy inducer;
Autophagy inhibitor;
Experimental autoimmune encephalomyelitis;
Inflammatory bowel disease;
Rheumatoid arthritis;
Systemic lupus erythematosus
- From:
Acta Pharmaceutica Sinica B
2021;11(11):3364-3378
- CountryChina
- Language:English
-
Abstract:
As a cellular bulk degradation and survival mechanism, autophagy is implicated in diverse biological processes. Genome-wide association studies have revealed the link between autophagy gene polymorphisms and susceptibility of autoimmune diseases including systemic lupus erythematosus (SLE) and inflammatory bowel disease (IBD), indicating that autophagy dysregulation may be involved in the development of autoimmune diseases. A series of autophagy modulators have displayed protective effects on autoimmune disease models, highlighting the emerging role of autophagy modulators in treating autoimmune diseases. This review explores the roles of autophagy in the autoimmune diseases, with emphasis on four major autoimmune diseases [SLE, rheumatoid arthritis (RA), IBD, and experimental autoimmune encephalomyelitis (EAE)]. More importantly, the therapeutic potentials of small molecular autophagy modulators (including autophagy inducers and inhibitors) on autoimmune diseases are comprehensively analyzed.
